Pipeline

Candidate

  • Discovery
  • ADME/PoC
  • IND Enabling
  • Phase 1
  • Phase 2
Collaborator
Borestrant

ER+/HER2- Breast Cancer

Zenopharm

Oral Selective Estrogen Receptor Degrader targeting Estrogen Receptor (ER) Breast Cancer

ER-PROTAC

ER+/HER2- Breast Cancer

Endotarget

Oral PROTAC degrader targeting Estrogen Receptor (ER) for Breast Cancer

BTK-PROTAC

Hematologic Malignancy

Endotarget

Oral PROTAC degrader for Bruton’s Tyrosine Kinase (BTK) for hematological cancers and auto-immune disorders

Carvisiran (+EN LNP)

Cervical Cancer, H&N Cancer

siRNA drug targeting Human Papilloma Virus (HPV) mediated cancers

Mevisiran (+EN LNP)

NSCLC, Pancreas Cancer

siRNA drug targeting Phosphomevalonate kinase (PMVK) for Radio-Sensitizer

Corpitenib

CRC, mCRC

Small-molecule targeting SERTA domain-containing protein 1 (SERTAD1) for colorectal cancer

Borestrant Phase 1
ER+/HER2- Breast Cancer Collaborator : Zenopharm

Oral Selective Estrogen Receptor Degrader targeting Estrogen Receptor (ER) Breast Cancer

ER-PROTAC IND Enabling
ER+/HER2- Breast Cancer Collaborator : Endotarget

Oral PROTAC degrader targeting Estrogen Receptor (ER) for Breast Cancer

BTK-PROTAC ADME/PoC
Hematologic Malignancy Collaborator : Endotarget

Oral PROTAC degrader for Bruton’s Tyrosine Kinase (BTK) for hematological cancers and auto-immune disorders

Carvisiran (+EN LNP) IND Enabling
Cervical Cancer, H&N Cancer

siRNA drug targeting Human Papilloma Virus (HPV) mediated cancers

Mevisiran (+EN LNP) ADME/PoC
NSCLC, Pancreas Cancer

siRNA drug targeting Phosphomevalonate kinase (PMVK) for Radio-Sensitizer

Corpitenib ADME/PoC
CRC, mCRC

Small-molecule targeting SERTA domain-containing protein 1 (SERTAD1) for colorectal cancer

Technology

EN LNP (Lipid Nano Particle)

LNP for mRNA based vaccine, siRNA therapeutics, Therapeutic protein replacement, Genome editing and Cell engineering

EN LNP (Lipid Nano Particle)

LNP for mRNA based vaccine, siRNA therapeutics, Therapeutic protein replacement, Genome editing and Cell engineering